For the estimated 1.3 million Americans living with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), treatment options remain frustratingly limited. The condition—characterized by debilitating fatigue, post-exertional malaise, cognitive dysfunction, and orthostatic intolerance—has no FDA-approved pharmacological therapy. Against this backdrop, a new prospective cohort study from Germany’s prestigious Charité – Universitätsmedizin Berlin offers a glimmer of mechanistic insight, though not a definitive solution.
What the Berlin Study Found
Published June 5, 2026, in the Journal of Translational Medicine, the study tracked thirty ME/CFS patients through a standardized course of forty hyperbaric oxygen therapy (HBOT) sessions. Researchers led by Dr. Carmen Scheibenbogen and colleagues employed a rigorous battery of assessments: validated symptom questionnaires, exercise capacity testing, handgrip strength measurements, cognitive batteries, orthostatic challenge protocols, and functional magnetic resonance imaging (fMRI) to probe brain connectivity changes.
The results, while preliminary, were statistically significant across multiple domains. The primary outcome—physical functioning as measured by the SF-36 Health Survey—improved with a moderate-to-large effect size (Cohen’s d = 0.71, p = 0.006). Pain scores on the same instrument dropped substantially (d = 0.79, p = 0.002), and the Chalder Fatigue Scale showed a marked reduction in symptom severity (d = −0.87, p < 0.001).
Beyond self-reported symptoms, objective measures shifted as well. Exercise capacity improved (d = 0.66), as did muscle strength (d = 0.40) and information processing speed (d = 0.52). Importantly for a population often sensitive to interventions, treatment adherence was high and tolerability favorable, with no major adverse events reported across the 1,200 total sessions delivered.
Brain Imaging Reveals Mechanistic Clues
Perhaps most intriguing were the neuroimaging findings. At baseline, ME/CFS patients showed hyperconnectivity between the thalamus and sensorimotor and visuo-occipital brain regions compared to healthy controls—patterns that normalized following HBOT treatment. The thalamus, often described as the brain’s relay station, regulates sensory gating, sleep-wake cycles, and autonomic function—all systems disrupted in ME/CFS.
This normalization of thalamic functional connectivity suggests HBOT may modulate the neuroinflammatory or metabolic disturbances hypothesized to underlie ME/CFS pathophysiology. The observation aligns with emerging research on HBOT’s effects in related post-viral conditions, including long COVID, where similar patterns of neuroinflammation and autonomic dysregulation have been documented.
The Critical Context: Evidence Quality and Regulatory Status
Before patients or clinicians draw conclusions, the study’s limitations demand scrutiny. This was a prospective cohort study, not a randomized controlled trial (RCT). Without a sham-controlled comparison group, placebo effects and natural symptom fluctuation cannot be excluded. The authors themselves acknowledge that “evidence remains limited” for HBOT in ME/CFS—a characterization that applies equally to most interventions in this poorly understood condition.
More consequentially for U.S. patients, HBOT is not FDA-cleared for ME/CFS. The agency’s consumer guidance explicitly states that hyperbaric oxygen therapy is not proven for conditions including chronic fatigue syndrome, and its use for such indications falls outside approved labeling. The FDA has cleared HBOT for fourteen specific indications—principally decompression sickness, carbon monoxide poisoning, certain non-healing wounds, late radiation tissue injury, and gas gangrene—but ME/CFS is not among them.
This regulatory gap has practical implications. Without FDA clearance, insurance coverage for HBOT in ME/CFS is virtually nonexistent. Patients pursuing treatment typically pay out-of-pocket, often at substantial cost, and must navigate a marketplace where clinic quality varies considerably.
Safety Considerations in an Unregulated Space
The FDA’s March 2025 letter to healthcare providers adds another layer of caution. The agency warned of fire risks and other safety hazards when HBOT devices are used improperly, particularly in non-accredited facilities or home settings. While the Berlin study employed hospital-based, medically supervised treatment, the growing proliferation of “soft” or mild hyperbaric chambers in wellness centers and private homes raises concerns about whether similar safety standards apply in the consumer market.
The Undersea and Hyperbaric Medical Society (UHMS), the leading professional body in the field, maintains that HBOT should be administered in accredited facilities with appropriate medical oversight—recommendations that carry particular weight for medically complex populations like ME/CFS patients.
Where the Research Goes Next
The Charité findings justify further investigation, but they do not establish HBOT as a standard-of-care treatment for ME/CFS. What would move the needle? A randomized, sham-controlled trial with adequate power, longer follow-up, and predefined responder analyses would address the methodological limitations of the current study. Such trials are notoriously difficult and expensive in ME/CFS, where patient heterogeneity and symptom fluctuation complicate endpoint assessment.
The overlap between ME/CFS and long COVID—estimated to affect millions following SARS-CoV-2 infection—may accelerate research interest. Both conditions share features of post-viral dysautonomia and neuroinflammation, and HBOT is already being explored in long COVID trials. If those studies yield positive results, they could indirectly strengthen the evidentiary foundation for ME/CFS as well.
The Bottom Line
For ME/CFS patients desperate for effective treatments, the Berlin study offers cautious encouragement: a signal of potential benefit, grounded in both symptomatic and neuroimaging outcomes, delivered with reasonable safety in a controlled setting. But the distance between a single cohort study and clinical practice remains substantial. Without FDA clearance, insurance coverage, or definitive efficacy data, HBOT for ME/CFS sits in the familiar limbo of promising-but-unproven interventions—worth watching, but not yet worth betting everything on.
As research continues, patients should consult knowledgeable clinicians, consider enrollment in clinical trials where available, and maintain realistic expectations about what hyperbaric oxygen can and cannot deliver for this challenging condition.